Continuous glucose monitoring improves glycemic control and reduces complications in gestational diabetes mellitusContinuous Glucose Monitoring Improves Blood Sugar Control in Pregnancy

Diabetes research and clinical practice Published September 1, 2026 Study authors: Yang Shirlyn, Boon Emelia Tze-Ting, Yang Qian, Chen Qing Yi, Shen Jiayi, Li Jie, Hu Yali, Wang Yufan… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider continuous glucose monitoring to improve glycemic control and reduce complications in gestational diabetes.

This meta-analysis evaluated the impact of continuous glucose monitoring (CGM) compared to self-monitoring of blood glucose (SMBG) in 5,650 pregnant women with gestational diabetes mellitus. The analysis focused on glycemic control measures, maternal events, and neonatal events.

Key findings indicate that CGM significantly improves glycemic control. Specifically, CGM resulted in a mean blood glucose reduction of 0.24 mmol/L (95% CI: -0.41, -0.06), a coefficient-of-variation reduction of 0.78% (95% CI: -1.50, -0.06), and a mean amplitude of glycemic excursions reduction of 0.22 mmol/L (95% CI: -0.43, -0.02). Additionally, time-above-range > 7.8 mmol/L decreased by 2.19% (95% CI: -3.78, -0.60). While not statistically confirmed by a p-value, CGM was associated with a 21% increase in medication use.

Regarding clinical outcomes, the study reported a reduction in adverse maternal and neonatal outcomes, such as caesarean delivery, macrosomia, neonatal hypoglycemia, and hyperbilirubinemia, by 8-35%. However, the authors note that the evidence remains inconsistent. Clinically, CGM may support better glycemic management and reduced complications in gestational diabetes, though the strength of the evidence for outcome reduction is limited by inconsistency.

How this fits prior evidence

This meta-analysis extends the evidence regarding management of gestational diabetes mellitus. It builds upon previous findings that pharmacologic treatments for gestational diabetes mellitus show varying impacts on glucose and neonatal outcomes. While pharmacologic interventions are established for glucose control, this finding suggests that continuous glucose monitoring provides superior glycemic metrics compared to standard self-monitoring, potentially contributing to the reduction of complications like macrosomia and neonatal hypoglycemia.

A large review of data from 5,650 pregnant women with gestational diabetes looked at how continuous glucose monitoring (CGM) compares to traditional finger-stick blood glucose monitoring (SMBG). The study focused on how well these methods managed blood sugar levels and the impact on both the mother and the baby.

The results showed that using a CGM device led to lower average blood glucose levels and less variation in sugar levels. It also reduced the amount of time blood sugar stayed above the target range. While the study did not provide specific safety data, it did note a 21 percent increase in medication use among those using the CGM device.

Additionally, the study found a link between using CGM and a reduction in certain complications, such as large birth size and neonatal issues. However, the data for these specific complications was reported as a range of 8 to 35 percent. Because the evidence for some of these outcomes is inconsistent, these findings should be viewed as a helpful guide rather than a certainty. Talk with your healthcare provider to see if this technology is right for your specific needs.

What this means for you:

Continuous glucose monitoring may improve blood sugar control and reduce some complications in gestational diabetes.

Common questions

How does continuous glucose monitoring help with gestational diabetes?

Continuous glucose monitoring (CGM) helps by providing more consistent data. The study found that CGM led to lower mean blood glucose levels and a lower coefficient of variation. It also reduced the amount of time blood sugar stayed above the target range of 7.8 mmol/L compared to traditional finger-stick methods.

Can this technology reduce risks for the baby?

The study reported a reduction in several adverse outcomes for both mother and baby, including caesarean delivery, macrosomia, neonatal hypoglycemia, and hyperbilirubinemia. These reductions were reported in a range of 8 to 35 percent. You should discuss these specific risks with your doctor.

Does using a CGM device change medication needs?

The study found a 21 percent increase in medication use among the group using continuous glucose monitoring. Because the evidence for some outcomes is inconsistent, your doctor can help determine how your specific treatment plan might change with this technology.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedSep 2026

PMID42595054

View Original Abstract ↓

Continuous glucose monitoring (CGM) may offer advantages over self-monitored blood glucose (SMBG) in gestational diabetes mellitus (GDM)-complicated pregnancies, but evidence remains inconsistent. We conducted a systematic review and meta-analysis of randomised controlled trials and observational studies published between January 1980 and April 2026 in PubMed, Embase, Scopus, Cochrane Library, and Web of Science, comparing CGM with SMBG in GDM pregnancies. The review was preregistered with PROSPERO (CRD420251084931). Primary outcomes were glycaemic control measures; secondary outcomes included maternal and neonatal events. Risk of bias was assessed using the Jadad scale and Newcastle-Ottawa Scale. Pooled risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Twenty-one studies involving 5,650 pregnant women were included, with low-to-moderate bias risks. Compared with SMBG, CGM significantly lower mean blood glucose (MD -0.24 mmol/L; 95% CI: -0.41, -0.06), coefficient-of-variation (-0.78%; -1.50, -0.06), mean amplitude of glycaemic excursions (-0.22 mmol/L; -0.43, -0.02), and time-above-range > 7.8 mmol/L (-2.19%, -3.78, -0.60). CGM was also associated with an 21% increase in medication use and an 8-35% reduction in adverse maternal and neonatal outcomes, including caesarean delivery, macrosomia, neonatal hypoglycaemia, and hyperbilirubinemia. These findings suggest CGM improves glycaemic control in GDM and reduces maternal and neonatal complications.

Continuous glucose monitoring improves glycemic control and reduces complications in gestational diabetes mellitusContinuous Glucose Monitoring Improves Blood Sugar Control in Pregnancy

How this fits prior evidence

Common questions

Study Details

Efficacy and Safety Profile of Subcutaneous Semaglutide for Weight Management in Adults

Semaglutide helps people with obesity lose significant body weight

Clinical research that matters. Delivered to your inbox.

Continuous glucose monitoring improves glycemic control and reduces complications in gestational diabetes mellitusContinuous Glucose Monitoring Improves Blood Sugar Control in Pregnancy

How this fits prior evidence

Common questions

More on Gestational Diabetes Mellitus

Study Details

Efficacy and Safety Profile of Subcutaneous Semaglutide for Weight Management in Adults

Semaglutide helps people with obesity lose significant body weight

Clinical research that matters. Delivered to your inbox.

Related in Diabetes & Endocrinology

From Other Specialties